Publication:
Role of Melatonin and Luzindole in Rat Mammary Cancer

Simple item page
dc.contributor.authorYEGEN, BERRAK
dc.contributor.authorsUmit, Ugurlu M.; Berna, Terzioglu; Handan, Kaya; Ipek, Erbarut; Berrak, Yegen; Can, Erzik; Bahadir, Gulluoglu M.
dc.date.accessioned2022-03-12T18:05:26Z
dc.date.available2022-03-12T18:05:26Z
dc.date.issued2012
dc.description.abstractBackground: Recent studies have analyzed the efficacy of various agents in experimental chemoprevention trials. In our study, the effects of melatonin (Mel) and its antagonist Luzindole (Luz) on Heme oxygenase-1 (HO-1) in a NMU (N-methyl-N-nitrosourea)-induced rat mammary carcinoma model are investigated. We aim to demonstrate the relationship between Mel and HO-1. Methods: Spraque-Dawley rats were treated with NMU at age 55 days to induce mammary carcinoma. Forty-eight rats were divided into four groups consisting of: (a) physiological saline group (PSG); (b) control group, NMU is given; (c) Mel group (500 mu g daily); (d) Mel antagonist Luz group (0.25 mg/kg/day i.p.). The animals were sacrificed; their serum and tissues were sampled for histopathologic evaluation, markers of endocrine derangement (serum prolactin, estradiol, and progesterone levels), apoptotic changes, DNA fragmentation, markers of oxidative stress and HO-1 immune expression were measured. Results: Most tumors developed in the Luz group (42%), followed by the control group (33%), and the Mel group (17%). The tumor latency was longer in Mel-treated group (control and Luz at week 17, Mel at week 21). The maximum tumor volume was also smaller in Mel group when compared to control and Luz groups (p < .05). In Mel group estradiol, progesterone, and prolactin levels were decreased compared to control group (p < .001; p < .01; and p < .01) and levels of apoptotic activity and DNA fragmentation ratio increased. Conclusions: The increment of HO-1 expression with Mel is described; possible underlying mechanisms of these effects await further investigations.
dc.identifier.doi10.3109/08941939.2012.665570
dc.identifier.eissn1521-0553
dc.identifier.issn0894-1939
dc.identifier.pubmed23215791
dc.identifier.urihttps://hdl.handle.net/11424/230687
dc.identifier.wosWOS:000311897200001
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS INC
dc.relation.ispartofJOURNAL OF INVESTIGATIVE SURGERY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectmelatonin
dc.subjectluzindole
dc.subjectheme oxygenase-1
dc.subjectrat
dc.subjectmammary cancer
dc.subjectBREAST-CANCER
dc.subjectDIPHENYLAMINE REACTION
dc.subjectHEME OXYGENASE
dc.subjectGROWTH-HORMONE
dc.subjectEXPRESSION
dc.subjectPROLACTIN
dc.subjectINFLAMMATION
dc.subjectESTROGENS
dc.titleRole of Melatonin and Luzindole in Rat Mammary Cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.id2a131d39-c28b-4536-8c0a-fe3fd3032fc1
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages9
oaire.citation.endPage353
oaire.citation.issue6
oaire.citation.startPage345
oaire.citation.titleJOURNAL OF INVESTIGATIVE SURGERY
oaire.citation.volume25
relation.isAuthorOfPublicatione4eaf9ac-f8dc-4e2b-b940-895cc906790d
relation.isAuthorOfPublication.latestForDiscoverye4eaf9ac-f8dc-4e2b-b940-895cc906790d

Files

Collections

Research Outputs